EU Panel endorses AstraZeneca’s breast cancer drug Truqap
LONDON: The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of AstraZeneca’s drug Truqap, in combination with Faslodex,...
AstraZeneca reports strong growth in 2023 despite COVID-19 challenges
AstraZeneca, a global biopharmaceutical company, announced its financial results for the full year 2023, showing a 6% increase in total revenue and a 15% increase...
AstraZeneca’s Truqap approved in US for advanced breast cancer
LONDON: AstraZeneca announced that its drug Truqap (capivasertib) has received approval from the US Food and Drug Administration (FDA) for the treatment of a specific...